Nutrition and NSCLC; Should We Administer Food Supplements?

Author(s): Paul Zarogoulidis*, Christoforos Kosmidis, Isaak Kesisoglou, Kosmas Tsakiridis, Wolfgang Hohenforst-Schmidt, Haidong Huang, Κonstantinos Romanidis, Anastasios Vagionas, Konstantinos Sapalidis

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 34 , 2021


Become EABM
Become Reviewer
Call for Editor

Abstract:

Non-small cell lung cancer is usually diagnosed at the advanced stage of the disease. We have novel diagnostic tools. However, prevention is still the best way to deal with this disease. Patients receive different treatments with different adverse effects. Targeted treatment with tyrosine kinase inhibitors and immunotherapy have entered everyday clinical practice. The nutritional status of a patient plays a crucial role in the treatment of the patient. Cachexia is observed in most cancer patients, and it has been identified as an independent factor in the overall survival of the patient. The improvement of nutritional status and metabolism directly impacts the quality of life, daily living, and overall survival of a lung cancer patient. We conducted a search on PubMed and Scopus and identified relevant publications. In this review, we will focus on the nutritional status of NSCLC patients and how food supplements assist in the QoL based on published literature. Additional information from other cancer types will be included where necessary.

Keywords: NSCLC, nutrition, immunotherapy, chemotherapy, tyrosine kinase inhibitors, cancer.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 27
ISSUE: 34
Year: 2021
Published on: 11 January, 2021
Page: [3602 - 3608]
Pages: 7
DOI: 10.2174/1381612827999210111193133
Price: $65

Article Metrics

PDF: 187